Albireo Pharma, Inc.

NasdaqCM:ALBO 주식 보고서

시가총액: US$921.1m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Albireo Pharma 관리

관리 기준 확인 2/4

주요 정보

Ron Cooper

최고 경영자

US$6.0m

총 보상

CEO 급여 비율9.8%
CEO 임기7.7yrs
CEO 소유권0.2%
경영진 평균 재임 기간4.2yrs
이사회 평균 재임 기간5.5yrs

최근 관리 업데이트

Recent updates

We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely

Jan 02
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely

Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt

Oct 25
Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt

Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome

Oct 11

Albireo Pharma: Assessing The Sagard Deal

Oct 03

Albireo gains on royalty agreement for pruritus therapy

Sep 22

Albireo gets reimbursed access to liver disease drug Bylvay in Italy

Sep 06

These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts

Aug 23
These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts

Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M

Aug 15

Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation

Jul 22

Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt

May 10
Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt

Albireo: A Speculative Play With Upside

May 03

Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?

Feb 02
Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?

Albireo: Successful And Accelerating Global Launch Drives Sales Revenue

Jan 31

Albireo: Reasons For A Successful Transformation Into A Commercial Company

Nov 24

Albireo Pharma: A Post Approval Assessment

Aug 09

Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress

Jun 21

Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year

Jun 11
Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year

Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat

Apr 26

Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts

Feb 27
Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts

Albireo launches late-stage trial of odevixibat in Alagille Syndrome

Dec 17

Albireo submits U.S. and European applications for odevixibat in liver disease

Dec 09

Albireo Pharma (ALBO) Investor Presentation - Slideshow

Nov 17

Albireo Pharma's odevixibat shows durable response in a rare pediatric liver disease

Nov 13

CEO 보상 분석

Ron Cooper 의 보수는 Albireo Pharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2022n/an/a

-US$131m

Jun 30 2022n/an/a

-US$36m

Mar 31 2022n/an/a

-US$33m

Dec 31 2021US$6mUS$590k

-US$34m

Sep 30 2021n/an/a

-US$48m

Jun 30 2021n/an/a

-US$136m

Mar 31 2021n/an/a

-US$120m

Dec 31 2020US$3mUS$570k

-US$108m

Sep 30 2020n/an/a

-US$90m

Jun 30 2020n/an/a

-US$82m

Mar 31 2020n/an/a

-US$78m

Dec 31 2019US$3mUS$551k

-US$63m

Sep 30 2019n/an/a

-US$71m

Jun 30 2019n/an/a

-US$63m

Mar 31 2019n/an/a

-US$61m

Dec 31 2018US$4mUS$530k

-US$46m

Sep 30 2018n/an/a

-US$35m

Jun 30 2018n/an/a

-US$28m

Mar 31 2018n/an/a

-US$19m

Dec 31 2017US$2mUS$460k

-US$24m

Sep 30 2017n/an/a

-US$31m

Jun 30 2017n/an/a

-US$28m

Mar 31 2017n/an/a

-US$20m

Dec 31 2016US$4mUS$400k

-US$16m

보상 대 시장: Ron's total compensation ($USD6.04M) is above average for companies of similar size in the US market ($USD3.58M).

보상과 수익: Ron's compensation has increased whilst the company is unprofitable.

CEO

Ron Cooper (59 yo)

7.7yrs

테뉴어

US$6,041,334

보상

Mr. Ronald H. W. Cooper, also known as Ron, serves as Independent Director at Generation Bio Co. since March 2021. He has been the Chief Executive Officer and President of Albireo Pharma Inc. since July 20...

리더십 팀

이름위치테뉴어보상소유권
Ronald H. Cooper
CEO, President & Director7.7yrsUS$6.04m0.16%
$ 1.5m
Simon Nicolas Harford
CFO & Treasurer4.4yrsUS$1.71m0.066%
$ 606.6k
Martha Carter
Chief Regulatory Officer6.3yrsUS$1.73m0.018%
$ 161.4k
Per-Goran Gillberg
Co-Founder & VP of Developmentno data데이터 없음데이터 없음
Jan Mattsson
Chief Scientific Officer15.2yrsUS$1.40m0.17%
$ 1.6m
Joan Connolly
Chief Technology Officer1.9yrs데이터 없음데이터 없음
Jason Duncan
Chief Legal Officer4.8yrs데이터 없음0.016%
$ 145.5k
Michelle Graham
Chief Human Resources Officer3.3yrs데이터 없음0.027%
$ 244.7k
Kristina Torfgard
VP & Global Project Headno data데이터 없음데이터 없음
Pamela Stephenson
Chief Commercial Officer4yrsUS$1.96m0.11%
$ 982.0k
Constantine Chinoporos
Chief Business Officer1.3yrs데이터 없음데이터 없음
Paul Streck
Chief Medical Officerless than a year데이터 없음데이터 없음

4.2yrs

평균 재임 기간

58.5yo

평균 연령

경험이 풍부한 관리: ALBO's management team is considered experienced (4.2 years average tenure).

이사회 구성원

이름위치테뉴어보상소유권
Ronald H. Cooper
CEO, President & Director7.5yrsUS$6.04m0.16%
$ 1.5m
David Chiswell
Independent Chairman of the Board15.1yrsUS$282.44k0.27%
$ 2.5m
Davey Scoon
Independent Director6.3yrsUS$266.82k0.14%
$ 1.3m
Michael Gutch
Independent Director7.4yrsUS$264.94k0.13%
$ 1.2m
Craig Hopkinson
Directorless than a year데이터 없음데이터 없음
Habib Dable
Independent Directorless than a year데이터 없음데이터 없음
Stephanie Okey
Independent Director4.8yrsUS$249.94k0.14%
$ 1.3m
Susan Alesina
Directorless than a year데이터 없음데이터 없음

5.5yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: ALBO's board of directors are considered experienced (5.5 years average tenure).